优化甲基化DNA标志物以排除异常子宫出血患者的子宫内膜癌
本研究前瞻性纳入≥45岁异常子宫出血/绝经后出血患者及≥18岁子宫内膜癌或非典型增生患者,通过自采阴道液棉塞检测甲基化DNA标志物。从19个标志物精简至12个后,最终筛选出2个标志物的panel,在独立测试集中检测子宫内膜癌的敏感性为96%(84-99%),特异性为82%(67-91%),AUC为0.97(0.94-1)。
要点
- 2-MDM模型在独立测试集中检测EC的敏感性96%、特异性82%、AUC 0.97。
- 19-MDM模型在独立集中敏感性91%、特异性87%。
- 自采阴道液检测甲基化DNA标志物可用于微创排查EC。
核心结论
- 从19个甲基化DNA标志物严格精简至12个后,筛选出的2-MDM panel在阴道液中检测子宫内膜癌具有高敏感性和特异性。
研究设计与样本
- 前瞻性研究,纳入≥45岁异常子宫出血/绝经后出血患者或≥18岁子宫内膜癌/非典型增生患者,自采阴道液棉塞。
主要发现
- 19-MDM模型在独立集中检测EC的敏感性为91%(83-96%),在良性子宫内膜中特异性为87%(80-92%)。
- 2-MDM模型在独立测试集中检测EC的敏感性为96%(84-99%),特异性为82%(67-91%),AUC为0.97(0.94-1)。
关键数值与推荐
- 19-MDM模型:EC敏感性91%(83-96%),BE特异性87%(80-92%)。
- 2-MDM模型:EC敏感性96%(84-99%),特异性82%(67-91%),AUC 0.97(0.94-1)。
临床怎么用
- 对于异常子宫出血/绝经后出血患者,自采阴道液检测2-MDM panel可能作为微创手段帮助排除子宫内膜癌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: While only 5-10% of postmenopausal bleeding (PMB) and perimenopausal abnormal uterine bleeding (AUB) represents an underlying endometrial cancer (EC) or precancerous lesion, the current standard of care recommends endometrial sampling to evaluate all presenting with this clinical concern. We aimed to develop a highly sensitive panel of methylated DNA markers (MDMs) to identify patients with underlying EC through less invasive testing of self-collected vaginal fluid. METHODS: Patients with AUB/PMB ≥45 years or EC or atypical endometrial hyperplasia (AEH) ≥18 years were prospectively enrolled to self-collect vaginal fluid using a tampon. Bisulfite-converted DNA from vaginal fluid was assayed with long-probe quantitative amplified signal (LQAS) for the quantification of MDM signal. Samples were tested with the goal of building a parsimonious model to discriminate EC from benign endometrium (BE). This marker reduction study started with 19 previously identified MDMs. Down-selection was then performed on a panel of 12 MDMs in an independent marker selection study. A random forest model was developed and validated in an independent test set. RESULTS: In marker reduction, a 19-MDM model achieved a sensitivity of 91% (83-96%) in EC with a specificity of 87% (80-92%) observed in BE in an independent set. In marker selection, a 2-MDM model generated a sensitivity for EC of 96% (84-99%), specificity of 82% (67-91%), and an AUC of 0.97 (0.94-1) in an independent test set. CONCLUSIONS: Rigorous marker reduction from 19 MDMs to 12 allowed for marker selection of a 2-MDM panel with high sensitivity and specificity to detect EC in vaginal fluid.
引用
- Bakkum-Gamez JN, Harrington SP, Slettedahl SW, et al. Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding. Gynecol Oncol. 2026. PMID: 41965218. doi:10.1016/j.ygyno.2026.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。